XtalPi
晶泰科技
AI- and robotics-driven platform for drug discovery and new materials R&D
- Headquarters
- Shenzhen, China
- Region
- Shenzhen
- Founded
- 2015
- Stage
- Public
Overview
XtalPi (2228.HK) was founded in 2015 in Shenzhen by three MIT postdoctoral researchers — Wen Shuhao, Ma Jian and Lai Lipeng. It combines quantum physics, artificial intelligence and cloud computing with automated robotic laboratories to provide drug discovery and new-materials R&D solutions. It listed on the Hong Kong Stock Exchange on 13 June 2024, becoming the first company to list under HKEX Chapter 18C for specialist technology companies, raising HKD 989.3 million. Investors include Tencent, 5Y Capital, Google, Susquehanna, Sino Biopharmaceutical and SoftBank Vision Fund. In August 2025 it signed a major pipeline collaboration agreement with DoveTree with a total order value of about HKD 47 billion. Revenue reached CNY 517 million in the first half of 2025, with adjusted net profit of CNY 142 million.
Products
3Intelligent Drug Discovery Platform
XtalCryo, XcelaHit, XceptionOp and XcelDev platforms covering crystal-structure prediction and hit discovery.
Automated Robotic Laboratories
Standardised intelligent robotic wet labs for high-throughput experimentation.
AI for New Materials
Extends its AI R&D platform to new materials such as solar panels and EV batteries.
Highlights
3- 01First company to list on HKEX under the Chapter 18C specialist technology regime (13 June 2024).
- 02Signed a pipeline collaboration with DoveTree worth about HKD 47 billion in August 2025.
- 03Revenue reached CNY 517 million in H1 2025, with adjusted net profit of CNY 142 million.
People
1
Funding
1- Source
IPO
HKD 8.96 亿
Events
0Not yet listed
Related projects
0Not yet listed
Topics
2Coverage
0Not yet listed
Information compiled from public sources; refer to the company's official website for authoritative details.